CytoDyn Inc. (CYDY) to Acquire Biotech Developing Therapies to Stop Cancer from Spreading
CytoDyn signs definitive agreement to acquire privately held ProstaGene Gets access to CCR5 technologies related to cancer Lead candidate PRO 140 set for Investigational New Drug (IND) application in first cancer indication, expanding CytoDyn’s focus beyond HIV With its planned acquisition of ProstaGene, LLC, CytoDyn Inc. (OTCQB: CYDY) is expanding its focus beyond HIV and graft-versus-host disease to open up a new front in the fight against cancer. ProstaGene is developing metastasis control technology that targets the chemokine receptor type 5 (CCR5), a protein on the surface of white blood cells. Metastasis is the spread of cancer beyond the original tumor,…